Investment
Features
FeesSafety
Academy
More
Pluang+

DeFi Development Corp. launches CHAD, a 14.3% yield SOL-backed preferred stock at $9.10, rated Buy.

Market News
08 Oct 2026
Seeking Alpha
View Source
Bullish
DeFi Development Corp. launches CHAD, a 14.3% yield SOL-backed preferred stock at $9.10, rated Buy.

DeFi Development Corp. has introduced CHAD, a preferred stock backed by Solana (SOL) that offers a 14.3% yield at a price of $9.10. The yield is supported not just by staking income but also by Solana validator rewards, treasury growth, and potential appreciation of SOL. Management expects CHAD to trade between $9.95 and $11, viewing a rise toward par value as a positive sign of the stock's structure. Key risks include volatility in SOL prices, adjustments in dividend rates, potential dilution from capital raising, and liquidity concerns due to CHAD's recent market launch.

The story covers CHAD, a preferred stock with a 14.3% yield backed by Solana. For readers following US stocks, here is Pluang's market snapshot as of Oct 08, 2026 16:51 WIB: out of 150 priced US stocks tradable on Pluang, 41 rose and 106 fell. Notable movers include OXY at USD 59.23 with a 1-day change of +1.75% and Pluang order activity of 98% Sell / 2% Buy, MRVL at USD 279.75 with a 1-day change of -1.73% and Pluang order activity of 36% Sell / 64% Buy, and DVN at USD 48.70 with a 1-day change of +1.71% and Pluang order activity of 8% Sell / 92% Buy.

More News

TIFF 2026 boosts Toronto spending by 12%, aiding small businesses and driving city-wide economic growth

TIFF 2026 boosts Toronto spending by 12%, aiding small businesses and driving city-wide economic growth

Visa Canada's data reveals that the Toronto International Film Festival (TIFF) 2026 increased visitor spending by 12% compared to 2025, with international visitors spending about 40% more than Canadian cardholders. The festival attracted visitors mai...

Market News
Bullish
53 minutes ago
Aclarion broadens CLARITY trial criteria to speed patient enrollment, keeping trial timeline on track.

Aclarion broadens CLARITY trial criteria to speed patient enrollment, keeping trial timeline on track.

Aclarion, Inc. has updated the enrollment criteria for its CLARITY clinical trial to better reflect real-world chronic low back pain patients and accelerate patient recruitment. The revised criteria, approved at most active sites, expand the pool of ...

Market News
Bullish
1 hour ago
Zscaler CEO Jay Chaudhry sells 2,852 shares for $550,000

Zscaler CEO Jay Chaudhry sells 2,852 shares for $550,000

Zscaler CEO Jay Chaudhry has sold 2,852 shares of the company, generating $550,000 from the transaction. This sale could indicate personal financial planning or portfolio rebalancing by the CEO. Investors might watch for any further insider activity ...

Market News
Bearish
2 hours ago
Ascentis Independent Advisors adds $1B in assets with four new advisory teams from Raymond James.

Ascentis Independent Advisors adds $1B in assets with four new advisory teams from Raymond James.

Ascentis Independent Advisors has expanded by adding four advisory teams from Raymond James Financial Services, bringing over $1 billion in client assets. These teams, based in California and Colorado, chose Ascentis to access enhanced planning, inve...

Market News
Bullish
2 hours ago
Orbit International reports $8.2M bookings in Q3 2026, surpassing 2025 total bookings for its power group.

Orbit International reports $8.2M bookings in Q3 2026, surpassing 2025 total bookings for its power group.

Orbit International Corp. announced consolidated bookings of approximately $8.2 million for Q3 2026, with deliveries expected to complete by Q1 2028. The Orbit Power Group (OPG) contributed over $3.8 million, exceeding 2025 total bookings by 24.6%, d...

Market News
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App